Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease.

Sise ME, Chute DF, Oppong Y, Davis MI, Long JD, Silva ST, Rusibamayila N, Jean-Francois D, Raji S, Zhao S, Thadhani R, Chung RT.

Kidney Int. 2019 May 15. pii: S0085-2538(19)30508-3. doi: 10.1016/j.kint.2019.04.030. [Epub ahead of print]

PMID:
31337501
2.

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT.

Curr Opin Organ Transplant. 2019 Jun;24(3):351-357. doi: 10.1097/MOT.0000000000000651.

PMID:
31090648
3.

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT.

Curr Opin Organ Transplant. 2019 Apr 16. doi: 10.1097/MOT.0000000000000651. [Epub ahead of print]

PMID:
31008739
4.

Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation.

Sise ME, Wojciechowski D, Chute DF, Gustafson J, Chung RT, Williams WW, Elias N.

Artif Organs. 2019 Apr 19. doi: 10.1111/aor.13473. [Epub ahead of print]

PMID:
31001828
5.

Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.

Sise ME, Seethapathy H, Reynolds KL.

Oncologist. 2019 Jun;24(6):735-742. doi: 10.1634/theoncologist.2018-0764. Epub 2019 Mar 22.

PMID:
30902916
6.

Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function.

Sise ME.

Kidney Int Rep. 2018 Dec 1;4(2):191-193. doi: 10.1016/j.ekir.2018.11.018. eCollection 2019 Feb. No abstract available.

7.

The association of hepatitis C infection with the onset of CKD and progression into ESRD.

Henson JB, Sise ME.

Semin Dial. 2019 Mar;32(2):108-118. doi: 10.1111/sdi.12759. Epub 2018 Nov 29. Review.

PMID:
30496620
8.

A Three-Headed Approach to Kidney Involvement in Rheumatic Diseases.

Bomback AS, Sise ME.

Rheum Dis Clin North Am. 2018 Nov;44(4):xiii-xiv. doi: 10.1016/j.rdc.2018.08.001. No abstract available.

PMID:
30274633
9.

Autoimmune Kidney Diseases Associated with Chronic Viral Infections.

Long JD, Rutledge SM, Sise ME.

Rheum Dis Clin North Am. 2018 Nov;44(4):675-698. doi: 10.1016/j.rdc.2018.06.006. Epub 2018 Sep 7. Review.

PMID:
30274630
10.

Hepatitis C virus infection and the kidney.

Sise ME.

Nephrol Dial Transplant. 2018 Jul 27. doi: 10.1093/ndt/gfy230. [Epub ahead of print] No abstract available.

11.

Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis.

Rutledge SM, Chung RT, Sise ME.

Hemodial Int. 2018 Apr;22 Suppl 1:S81-S96. doi: 10.1111/hdi.12649. Review.

PMID:
29694729
12.

Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients.

Sise ME, Chute DF, Gustafson JL, Wojciechowski D, Elias N, Chung RT, Williams WW.

Hemodial Int. 2018 Apr;22 Suppl 1:S71-S80. doi: 10.1111/hdi.12650. Review.

PMID:
29694722
13.

Effect of the Opioid Crisis on the Donor Pool for Kidney Transplantation: An Analysis of National Kidney Deceased Donor Trends from 2010-2016.

Chute DF, Sise ME.

Am J Nephrol. 2018;47(2):84-93. doi: 10.1159/000486516. Epub 2018 Feb 13.

PMID:
29439266
14.

Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.

Chute DF, Chung RT, Sise ME.

Kidney Int. 2018 Mar;93(3):560-567. doi: 10.1016/j.kint.2017.10.024. Epub 2018 Jan 9. Review.

PMID:
29325996
15.

When and how can nephrologists treat hepatitis C virus infection in dialysis patients?

Davis MI, Chute DF, Chung RT, Sise ME.

Semin Dial. 2018 Jan;31(1):26-36. doi: 10.1111/sdi.12650. Epub 2017 Sep 18. Review.

PMID:
28925068
16.

Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.

Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, Brancale J, Xu D, Wisocky J, Lin MV, Kim AY, Thadhani R, Chung RT.

Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1615-1623. doi: 10.2215/CJN.02510317. Epub 2017 Sep 7.

17.

Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.

Sise ME.

Hepatology. 2017 Oct;66(4):1335-1337. doi: 10.1002/hep.29339. Epub 2017 Aug 30. No abstract available.

PMID:
28650558
18.

Case 12-2017 - A 34-Year-Old Man with Nephropathy.

Sise ME, Lo GC, Goldstein RH, Allegretti AS, Masia R.

N Engl J Med. 2017 Apr 20;376(16):1575-1585. doi: 10.1056/NEJMcpc1616395. No abstract available.

PMID:
28423292
19.

Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection.

Hogan JJ, Lim MA, Palmer MB, Bloom RD, Chung RT, Sise ME.

Hepatology. 2017 Aug;66(2):658-660. doi: 10.1002/hep.29125. Epub 2017 Jun 22. No abstract available.

PMID:
28211090
20.

Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy.

Sise ME, Wisocky J, Rosales IA, Chute D, Holmes JA, Corapi KM, Babitt JL, Tangren JS, Hashemi N, Lundquist AL, Williams WW, Mount DB, Andersson KL, Rennke HG, Smith RN, Colvin R, Thadhani RI, Chung RT.

Kidney Int Rep. 2016 Sep;1(3):135-143.

21.

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.

Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV.

PLoS One. 2016 Jul 14;11(7):e0158431. doi: 10.1371/journal.pone.0158431. eCollection 2016.

22.

Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA; HCV-TARGET.

Liver Int. 2016 Jun;36(6):807-16. doi: 10.1111/liv.13102. Epub 2016 Mar 24.

23.

Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.

Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT.

Hepatology. 2016 Feb;63(2):408-17. doi: 10.1002/hep.28297. Epub 2015 Dec 11.

24.

Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.

Hundemer GL, Sise ME, Wisocky J, Ufere N, Friedman LS, Corey KE, Chung RT.

Infect Dis (Lond). 2015;47(12):924-9. doi: 10.3109/23744235.2015.1078908. Epub 2015 Aug 18.

25.

Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study.

Sise ME, Backman ES, Wenger JB, Wood BR, Sax PE, Chung RT, Thadhani R, Kim AY.

PLoS One. 2015 Apr 29;10(4):e0124139. doi: 10.1371/journal.pone.0124139. eCollection 2015.

26.

Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase.

Connors NJ, Sise ME, Nelson LS, Hoffman RS, Smith SW.

Clin Kidney J. 2014 Dec;7(6):590-2. doi: 10.1093/ckj/sfu093. Epub 2014 Sep 16.

27.

Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.

Sise ME, Hirsch JS, Canetta PA, Herlitz L, Mohan S.

AIDS. 2015 May 15;29(8):941-6. doi: 10.1097/QAD.0000000000000628.

PMID:
25784440
28.

Pulmonary hypertension in patients with chronic and end-stage kidney disease.

Sise ME, Courtwright AM, Channick RN.

Kidney Int. 2013 Oct;84(4):682-92. doi: 10.1038/ki.2013.186. Epub 2013 Jun 5. Review.

29.

Urinary neutrophil gelatinase associated lipocalin identifies neonates with high probability of sepsis.

Sise ME, Parravicini E, Barasch J.

Pediatrics. 2012 Oct;130(4):e1053-4; author reply e1055-7. doi: 10.1542/peds.2012-2302B. No abstract available.

PMID:
23035240
30.

NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease.

Nickolas TL, Forster CS, Sise ME, Barasch N, Sol√°-Del Valle D, Viltard M, Buchen C, Kupferman S, Carnevali ML, Bennett M, Mattei S, Bovino A, Argentiero L, Magnano A, Devarajan P, Mori K, Erdjument-Bromage H, Tempst P, Allegri L, Barasch J.

Kidney Int. 2012 Sep;82(6):718-22. doi: 10.1038/ki.2012.195. Epub 2012 Jun 13.

31.

Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.

Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL.

Dig Dis Sci. 2012 Sep;57(9):2362-70. doi: 10.1007/s10620-012-2180-x. Epub 2012 May 6.

32.

Urine neutrophil gelatinase-associated lipocalin identifies unilateral and bilateral urinary tract obstruction.

Sise ME, Forster C, Singer E, Sola-Del Valle D, Hahn B, Schmidt-Ott KM, Barasch J, Nickolas TL.

Nephrol Dial Transplant. 2011 Dec;26(12):4132-5. doi: 10.1093/ndt/gfr569. Epub 2011 Nov 1.

33.

Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy.

Sola-Del Valle DA, Mohan S, Cheng JT, Paragas NA, Sise ME, D'Agati VD, Barasch J.

Nephrol Dial Transplant. 2011 Jul;26(7):2387-90. doi: 10.1093/ndt/gfr258. Epub 2011 May 9.

34.

Urinary neutrophil gelatinase-associated lipocalin is a promising biomarker for late onset culture-positive sepsis in very low birth weight infants.

Parravicini E, Nemerofsky SL, Michelson KA, Huynh TK, Sise ME, Bateman DA, Lorenz JM, Barasch JM.

Pediatr Res. 2010 Jun;67(6):636-40. doi: 10.1203/PDR.0b013e3181da75c1.

35.

Reference values of urinary neutrophil gelatinase-associated lipocalin in very low birth weight infants.

Huynh TK, Bateman DA, Parravicini E, Lorenz JM, Nemerofsky SL, Sise ME, Bowman TM, Polesana E, Barasch JM.

Pediatr Res. 2009 Nov;66(5):528-32. doi: 10.1203/PDR.0b013e3181baa3dd.

36.

Elevated urine neutrophil gelatinase-associated lipocalin can diagnose acute kidney injury in patients with chronic kidney diseases.

Sise ME, Barasch J, Devarajan P, Nickolas TL.

Kidney Int. 2009 Jan;75(1):115-6; author reply 116. doi: 10.1038/ki.2008.529. No abstract available.

37.

Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury.

Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J.

Ann Intern Med. 2008 Jun 3;148(11):810-9.

Supplemental Content

Support Center